Peptide-PNA conjugates: Targeted transport of antisense therapeutics into tumors
Tumor-specific accumulation of antisense therapeutics: The conjugation of a receptor-binding peptide allows for the first time the selective transport of oligonucleotide analogues into tumor tissue. By using the tert-butyloxycarbonyl (Boc) protecting group stratergy, hybrids of peptide nucleic acids...
| Autores: | , , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión aceptada para publicación |
| Fecha de publicación: | 2003 |
| País: | España |
| Recursos: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/136724 |
| Acesso em linha: | http://hdl.handle.net/10261/136724 |
| Access Level: | acceso abierto |
| Palavra-chave: | Antisense agents Drug delivery Peptide nucleic acids Peptides Solid-phase synthesis |
| Resumo: | Tumor-specific accumulation of antisense therapeutics: The conjugation of a receptor-binding peptide allows for the first time the selective transport of oligonucleotide analogues into tumor tissue. By using the tert-butyloxycarbonyl (Boc) protecting group stratergy, hybrids of peptide nucleic acids and peptides are accessible that accumulate in tumor tissue at a tenfold higher concentration than the free peptide nucleic acid. |
|---|